Advertisement
Canada markets closed

  • S&P/TSX

    21,639.10
    -59.01 (-0.27%)
     

  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     

  • DOW

    38,589.16
    -57.94 (-0.15%)
     

  • CAD/USD

    0.7281
    +0.0001 (+0.02%)
     

  • CRUDE OIL

    78.49
    -0.13 (-0.17%)
     

  • Bitcoin CAD

    90,876.55
    -108.18 (-0.12%)
     

  • CMC Crypto 200

    1,403.34
    -14.54 (-1.03%)
     

  • GOLD FUTURES

    2,348.40
    +30.40 (+1.31%)
     

  • RUSSELL 2000

    2,006.16
    -32.75 (-1.61%)
     

  • 10-Yr Bond

    4.2130
    -0.0250 (-0.59%)
     

  • NASDAQ

    17,688.88
    +21.32 (+0.12%)
     

  • VOLATILITY

    12.66
    +0.72 (+6.03%)
     

  • FTSE

    8,146.86
    -16.81 (-0.21%)
     

  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     

  • CAD/EUR

    0.6798
    +0.0024 (+0.35%)
     

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·2 min read

FREMONT, Calif., May 17, 2024--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on May 15, 2024, a non-qualified stock option to purchase an aggregate of 85,000 shares of its common stock to Personalis’ new Vice President, Customer Experience under Personalis’ 2020 Inducement Plan.

The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee, or non-employee director, of Personalis, as an inducement material to such individual’s entering into employment with Personalis, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Personalis is making this announcement as required by Nasdaq rules.

The inducement stock option granted on May 15, 2024 has an exercise price of $1.43 per share, which is equal to the closing price of Personalis’ common stock on the grant date. The inducement stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and 1/36th of the remaining shares vesting monthly thereafter, subject to continued service through each applicable vesting date. The foregoing inducement award is subject to the terms and conditions of Personalis’ 2020 Inducement Plan, and the terms and conditions of the applicable award agreement covering the grant.

ADVERTISEMENT

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240517449525/en/

Contacts

Investor Relations Contact:
Caroline Corner
investors@personalis.com
415-202-5678

Media:
pr@personalis.com